By Marie Rosenthal, MS
SAN FRANCISCO—Adults with HIV who are virologically suppressed maintained that suppression and low virologic failure after switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) (Symtuza, Janssen Pharmaceuticals), according to a new report.
The researchers reported 96-week data from the ongoing phase 3 EMERALD study, an international multicenter randomized, open-label, parallel-group, noninferiority study evaluating the efficacy and